Zydus Lifesciences Limited (NSE:ZYDUSLIFE)
India
· Delayed Price · Currency is INR | Market Cap | 994.76B |
| Revenue (ttm) | 236.08B |
| Net Income (ttm) | 45.72B |
| Shares Out | 1.01B |
| EPS (ttm) | 45.44 |
| PE Ratio | 21.75 |
| Forward PE | 22.34 |
| Dividend | 11.00 (1.15%) |
| Ex-Dividend Date | Jul 25, 2025 |
| Volume | 717,183 |
| Average Volume | 870,235 |
| Open | 993.55 |
| Previous Close | 988.60 |
| Day's Range | 982.20 - 1,002.85 |
| 52-Week Range | 795.00 - 1,220.00 |
| Beta | 0.46 |
| RSI | 56.74 |
| Earnings Date | Aug 8, 2025 |
About Zydus Lifesciences
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pi... [Read more]
Financial Performance
In 2024, Zydus Lifesciences's revenue was 232.42 billion, an increase of 18.90% compared to the previous year's 195.47 billion. Earnings were 45.26 billion, an increase of 17.26%.
Financial StatementsNews
Stocks to watch on brokerages’ radar today, August 13: Minda Corp, Apollo Hospitals, Alkem Labs, Nykaa, Zydus Lifesciences, HAL, ONGC, NHPC, Honasa, Paytm
Brokerages have issued fresh calls and revised targets for several key companies, with updates spanning the auto ancillary, healthcare, pharma, defence, energy, and consumer sectors. Minda Corp share:...
Zydus Lifesciences Q1 net profit rises 3% to Rs 1,467 crore
India Business News: Zydus Lifesciences on Tuesday said its consolidated net profit increased 3 per cent year-on-year to Rs 1,467 crore for the first quarter ended June 30.
Zydus Lifesciences Q1 Results: Revenue rises 5.9% YoY to Rs 6,573.7 crore, Net profit up 3.7% YoY
Zydus Lifesciences reported a 5.9% year-on-year (YoY) increase in revenue from operations at Rs 6,573.7 crore for the quarter ended June 30, 2025, compared to Rs 6,207 crore in the same quarter last y...
Top Q1 results today, August 12: HAL, ONGC, Hindalco Industries, Zydus Lifesciences, Bharat Dynamics and more to announce earnings
As the June quarter results season approaches its final days, a significant number of prominent Indian companies are gearing up to announce their financial performance. Tuesday, August 12, 2025, will ...
Zydus Lifesciences gets USFDA final approval for Diltiazem Hydrochloride tablets
Zydus Lifesciences Limited, along with its subsidiaries and affiliates (collectively referred to as “Zydus”), has secured final approval from the United States Food and Drug Administration (USFDA) for...
Zydus Lifesciences gets USFDA nod for Prucalopride tablets, 1 mg and 2 mg
Zydus Lifesciences Limited has received final approval from the US Food and Drug Administration (USFDA) to market Prucalopride Tablets, 1 mg and 2 mg (reference listed drug: Motegrity®). The tablets a...
Zydus Lifesciences gets tentative approval from USFDA for Ibrutinib tablets
Zydus Lifesciences has received tentative approval from the USFDA to market Ibrutinib tablets in the 140 mg, 280 mg, and 420 mg strengths in the U.S. market. The drug is a generic version of Imbruvica...
Zydus Lifesciences secures USFDA approval for Celecoxib Capsules
Zydus Lifesciences has received final approval from the US Food and Drug Administration (USFDA) to market Celecoxib Capsules in the U.S. market. The approval covers four dosage strengths — 50 mg, 100 ...
Jefferies maintains buy on Zydus Lifesciences, sees 15.5% upside on resilient FY26 growth outlook
Jefferies has reaffirmed its Buy rating on Zydus Lifesciences with a target price of ₹1,150, implying a potential upside of 15.5% from the current market price of ₹996.00. The brokerage expressed conf...
Zydus completes USFDA inspection at oncology plant with two minor observations, none related to data integrity
Zydus Lifesciences Ltd has announced the successful conclusion of a Good Manufacturing Practices (GMP) follow-up inspection by the United States Food and Drug Administration (USFDA) at its oncology in...
Stocks to watch on June 12: Zydus Life, Adani Group, Tanla Platforms, HUL, Nazara Tech, MCX in focus
Markets will track a range of corporate developments and sectoral updates on Wednesday, June 12. Here’s a look at the key stocks in focus: Positive Triggers Zydus Lifesciences: Received Establishment ...
Zydus receives USFDA EIR for Ankleshwar API facility with ‘No Action Indicated’ status
Zydus Lifesciences Limited announced on Wednesday that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its API manufacturing f...
Zydus receives EIR with VAI classification from USFDA for Dabhasa API facility
Zydus Lifesciences has received the Establishment Inspection Report (EIR) from the USFDA for its API manufacturing facility at Dabhasa, near Vadodara. The inspection, conducted from April 21 to April ...
Top stocks to buy today: Stock recommendations for June 5, 2025
Top stock market recommendations: Aakash K Hindocha suggests a cautious outlook for Nifty and Bank Nifty, anticipating potential declines to 24300/24100 and 54700/54500, respectively. He recommends bu...
Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang
On Tuesday, Zydus Lifesciences Ltd. announced its entry into the global biologics contract development and manufacturing organization (CDMO) business through its plan to acquire Agenus Inc.’s (NASDAQ:...
Zydus secures licensing rights for next-gen immuno-oncology platforms from US-based Agenus
Zydus Lifesciences Limited, including its subsidiaries and affiliates (“Zydus”), has entered into an agreement with Agenus Inc. (NASDAQ: AGEN) to acquire the commercial rights for its investigational ...
Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the US
$75M upfront payment to Agenus for the transfer of manufacturing assets $50M of contingent payments to Agenus Exclusive license for BOT/BAL in India and Sri Lanka $16M equity investment at $7.50 per s...
Zydus receives tentative USFDA approval for Rifaximin Tablets, 550 mg
Zydus Lifesciences Limited, along with its subsidiaries and affiliates (collectively referred to as “Zydus”), has received tentative approval from the United States Food and Drug Administration (USFDA...
Top stocks to buy today: Stock recommendations for May 29, 2025
Top stock market recommendations: Nifty remains range-bound, potentially retesting lower supports unless it closes above 25050, while Bank Nifty's rising trendline break suggests a possible 1200-1500 ...
Zydus share price: Nomura sees 29% upside, upbeat on US growth and vaccine contribution
Nomura has retained its buy rating on Zydus Lifesciences with a target price of ₹1,140, implying an upside of nearly 29% from the current market price of ₹884.45. The brokerage acknowledges a Q4 EBITD...
Zydus Lifesciences FY 25 net profit rises 17%; co declares Rs 11 dividend
Zydus Lifesciences reported a 17.3% increase in FY25 consolidated net profit, reaching Rs 4,525.5 crore, driven by strong US and India sales. The US formulations business stood out with a 27.2% growth...
Zydus Lifesciences Q4 results: Revenue rises 18% YoY; Net profit flat at Rs 1,171 crore
Zydus Lifesciences reported a marginal decline in net profit for the fourth quarter ended March 31, 2025. The company posted a consolidated net profit of ₹1,171 crore, down from ₹1,182 crore in the co...
Q4 Results Today, May 20: NHPC, Dixon Technologies, Gland Pharma, Zydus Lifesciences, Hindalco among companies reporting earnings
A total of 146 companies are scheduled to release their financial results for the January-March quarter on Tuesday, May 20. These earnings reports will provide insight into the performance of these fi...
Zydus receives EIR from USFDA for its Ambernath API manufacturing facility
Zydus Lifesciences Ltd. has announced the receipt of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredient (API...
Zydus gets USFDA nod for generic version of Copaxone for treatment of Multiple Sclerosis
Zydus Lifesciences Limited announced on Thursday that it has received final approval from the United States Food and Drug Administration (USFDA) for its Glatiramer Acetate Injection, a generic version...